Purpose or Objective: Surgery is the cornerstone in the management of sarcomas. The aim of this study was to evaluate intensity-modulated radiotherapy (RT) with tomotherapy followed by surgery in terms of acute gastrointestinal (GI) toxicities, especially regarding the high-level of prescribed dose (54 Gy/30 fractions/6weeks).
Material and Methods:
From April 2009 to September 2013, 48 patients were included in a prospective multicenter study. Feasibility of tomotherapy, acute toxicities and local control at 3 years were the principal and secondary objectives. Inclusion criteria were operable, biopsy-proven, retroperitoneal liposarcoma. Patients with non-operable tumors validated after multi-disciplinary team evaluation, other histology or metastatic disease were excluded.Clinical Target Volume (CTV) and mains organs at risk (contralateral kidney, duodenum, bowel bag) were systematically delineated with the surgeon. Dose constraints to the bowel bag were defined as V45 Gy<33% and V30 Gy<50%. Surgery was planned 4 to 8 weeks after RT. Clinical visits were performed weekly during RT, before surgery, and 2 and 6 months after surgery. Toxicity was recorded according to CTCAE V4.0 scale.
Results:
For acute GI toxicity, 46/48 patients were evaluable. All patients completed the radio surgical schedule without dose reduction. Mean age was 62 years (36-82). All patients were OMS ≤2 except one (OMS=3). Mean CTV was 2954 cc (920-4989. Mean small bowel and duodenal volumes were 2725 (1355-4090) and 73 cc (33-113), respectively. Monobloc exerese was systematically achieved and all patients underwent homolateral nephrectomy. Twenty-nine patients underwent bowel resection, including large bowel (28/29), small bowel(4/29) and duodenum (1/29). Mean weight loss during RT was 5,4 kg (about 8% of mean body weight) and 8,9 kg at the first visit after surgery. At 2 months, grade 3 toxicities included duodenal stenosis (1/46), intestinal fistula (1/46) and enterocolitis (1/46) and grade 4 toxicity included GI fistula (1/46). At 6 months, no GI toxicities were observed. Three patients died within 6 months after surgery, 2 of which were related to treatment: one respiratory disorder 6 days after surgery and 1 duodenal perforation with necrosis and infection 4 months after surgery.
Conclusion:
For patients with retroperitoneal liposarcoma, preoperative 54 Gy RT appears feasible. Due to the low rate of severe complications, no statistic correlations with dose in digestive structure were performed.
EP-1399
Safety of concurrent adjuvant radiotherapy and chemotherapy for locally advanced soft tissue sarcoma D. Greto Purpose or Objective: The standard treatment of high grade soft tissue sarcoma (STS) is surgery followed by adjuvant radiotherapy (RT); chemotherapy (CT) can be an option in selected patients due to reported benefit in terms of disease free survival. The association of RT with CT might increase tissue reactions with the consequent risk of unplanned treatment interruptions resulting in an increased risk of treatment failure. This retrospective study analyze the safety and feasibility, respectively in terms of additional toxicity and compliance, of concurrent chemoradiotherapy (CTRT) in adjuvant treatment of STS.
Material and Methods:
Data of 84 STS patients treated with surgery and adjuvant RT from June 1994 to November 2014 at the University of Florence, were retrospectively collected. Anthracycline-based CT was performed in high risk patients. Acute and late local toxicity of RT treatment were assessed respectively by Common Terminology Criteria for Adverse Events (CTCAE) 4.0 and RTOG/EORTC criteria for the Late Radiation Toxicity. CT-related hematological Toxicity was assessed by CTCAE 4.0.
Results: Twenty-four (28.6%) patients received CTRT. Mean follow-up was 5.6 years (range 0.4-18.8). At the time of our analysis 8 (9,5%) patients had a local relapse, 17 (19.8%) developed distant metastases, and 14 (16.7%) died of metastatic disease. Local Recurrence Free Survival (LRFS), Distant Relapse Free Survival (DRFS) and Overall Survival (OS) were respectively 83.4%, 70% and 69.5%. Grade ≥3 leucopenia occurred in 6 CTRT patients, resulting in early interruption of the CT treatment in 3 cases. Skin acute toxicity was developed in 59 (70,2%) of patients ; G3 skin toxicity occurred in 19 (22.6%) cases and determined treatment interruption in 15 (17.9%) patients with a mean treatment
